SEC Comment Letter 0000000000-23-013703 to CERO THERAPEUTICS HOLDINGS, INC. (CERO)

CERO THERAPEUTICS HOLDINGS, INC.
Date: Dec. 15, 2023 · CIK: 0001870404 · Accession: 0000000000-23-013703

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-40877

Date

December 15, 2023

Author

Chris Ehrlich

Form

UPLOAD

Company

CERO THERAPEUTICS HOLDINGS, INC.

Letter

United States securities and exchange commission logo December 15, 2023 Chris Ehrlich Chief Executive Officer Phoenix Biotech Acquisition Corp. 2201 Broadway, Suite 705 Oakland, CA 94612 Re:Phoenix Biotech Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed November 27, 2023 File No. 001-40877 Dear Chris Ehrlich: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Letalien

Show Raw Text

United States securities and exchange commission logo
December 15, 2023
Chris Ehrlich
Chief Executive Officer
Phoenix Biotech Acquisition Corp.
2201 Broadway, Suite 705
Oakland, CA 94612
Re:Phoenix Biotech Acquisition Corp.
Preliminary Proxy Statement on Schedule 14A
Filed November 27, 2023
File No. 001-40877
Dear Chris Ehrlich:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jeffrey Letalien

SecProbe.io